Delivery Order HHSN261201200035I-HHSN26100004
Award Date 8/26/14
Potential Completion Date 10/25/22
Potential Value $827K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Evanston, IL 60208, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS), to Northwestern University. The contract is titled "CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH" and is a delivery order under the "Cancer Prevention Agent Development Program 2012-2017" indefinite delivery vehicle (IDV). The contract has a ceiling value of $2,031,555.74 and a period of...
- This is a federal contract award from the National Cancer Institute, part of the Department of Health and Human Services, to Northwestern University, a private research university, for a Cancer Prevention Agent Development Program project. The contract has a ceiling value of $946,472.83 and a period of performance ending August 31, 2023. The objective is to conduct a randomized, double-blind, placebo-controlled Phase II clinical trial examining the effects of simvastatin versus placebo on...
- This federal contract award was made by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Northwestern University, a private research university. The $96,000.31 award supports a Phase I clinical trial of the compound berberine in subjects with ulcerative colitis, as part of the agency's Cancer Prevention Agent Development Program. The contract has no set-aside designation. The prime contractor, Northwestern University, will oversee the...
- This federal contract award, with a ceiling value of $1,159,347.10, was issued by the National Cancer Institute (NCI) to Northwestern University. The contract is part of the NCI's "Cancer Prevention Agent Development Program: Early Phase Clinical Research" and involves a Phase IIB clinical trial to evaluate the efficacy of topical 4-hydroxytamoxifen versus oral tamoxifen in treating ductal carcinoma in situ (DCIS) of the breast. Northwestern University is the prime contractor, and...
- This is a $1,097,981.00 firm fixed price delivery order contract awarded by the National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is for research to evaluate the use of a novel therapy targeting the STAT3 signaling pathway to prevent the development of non-small cell lung cancer in patients with chronic obstructive pulmonary disease. This delivery order is issued under the PREVENT Preclinical Drug...
- This federal contract award was issued by the National Cancer Institute, a civilian agency under the U.S. Department of Health and Human Services, to the University of Illinois for a "CONTRACT ORIENTATION AND KICKOFF MEETING" from September 30, 2015 to December 31, 2015. The award, which has a ceiling value of $2,587.19, is a delivery order under the PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) indefinite delivery/indefinite quantity (IDIQ) contract. The contract has a...
- This is a definitive contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the University of Illinois for preclinical pharmacology and toxicology studies. The contract, valued at $24,207,156.38, does not have a set-aside designation. The University of Illinois, a major public research institution, is conducting research and development work to support the PREVENT Cancer Preclinical Drug Development Program, a structured...
- This federal contract award, issued by the National Cancer Institute, is for a Phase I single-arm, multicenter pilot study to validate Y-OHPDG as a biomarker and test the effects of Polyphenon E on its levels in patients with cirrhosis. The $1,410,682.11 contract was awarded to Northwestern University, which will serve as the prime contractor. Georgetown University and the University of Puerto Rico Medical Sciences Campus are listed as subcontractors. The contract is part of the National...
- This federal contract award, valued at $999,843.18, was issued by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) for a randomized phase II clinical trial evaluating the effects of low-dose aspirin versus placebo in high-risk individuals with CT screen-detected lung nodules. The contract is part of NCI's Cancer Prevention Agent Development Program and supports early-phase clinical research. MD Anderson has collaborated with several...
- The National Cancer Institute awarded Northwestern University a $250,000 firm fixed-price purchase order on November 1, 2024, for medical record abstraction services supporting the Pediatric Proton and Photon Therapy Comparison Cohort study. Under this 20-month contract extending through June 30, 2026, Northwestern University will retrieve and abstract de-identified clinical and treatment data from medical records of pediatric cancer patients treated with proton or photon radiotherapy. The...